11/18
01:35 pm
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $125.00 price target on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $125.00 price target on the stock.
11/18
01:35 pm
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $125.00 price target on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $125.00 price target on the stock.
11/18
12:52 pm
bpmc
Rating for BPMC
Low
Report
Rating for BPMC
11/18
12:52 pm
bpmc
Rating for BPMC
Low
Report
Rating for BPMC
11/15
08:04 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $135.00 price target on the stock.
Medium
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $135.00 price target on the stock.
11/15
08:04 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $135.00 price target on the stock.
Medium
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $135.00 price target on the stock.
11/15
05:06 am
bpmc
Rating for BPMC
Medium
Report
Rating for BPMC
11/15
05:06 am
bpmc
Rating for BPMC
Medium
Report
Rating for BPMC
11/14
06:29 pm
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $135.00 price target on the stock.
Medium
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $135.00 price target on the stock.
11/14
06:29 pm
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $135.00 price target on the stock.
Medium
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $135.00 price target on the stock.
11/14
07:35 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $126.00 price target on the stock.
Medium
Report
Blueprint Medicines Co. (NASDAQ: BPMC) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $126.00 price target on the stock.
11/14
07:32 am
bpmc
Rating for BPMC
Medium
Report
Rating for BPMC
10/31
03:46 pm
bpmc
Rating for BPMC
Low
Report
Rating for BPMC
10/31
03:46 pm
bpmc
Rating for BPMC
Low
Report
Rating for BPMC
10/31
08:35 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $135.00 price target on the stock.
Medium
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $135.00 price target on the stock.
10/31
06:29 am
bpmc
Rating for BPMC
Low
Report
Rating for BPMC
10/31
06:29 am
bpmc
Rating for BPMC
Low
Report
Rating for BPMC
10/30
08:00 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $133.00 price target on the stock.
Medium
Report
Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $133.00 price target on the stock.
10/30
07:48 am
bpmc
Rating for BPMC
Low
Report
Rating for BPMC
10/30
07:48 am
bpmc
Rating for BPMC
Low
Report
Rating for BPMC
10/24
07:49 am
bpmc
Rating for BPMC
Low
Report
Rating for BPMC
10/24
07:16 am
bpmc
Blueprint Medicines Co. (NASDAQ: BPMC) is now covered by analysts at UBS Group AG. They set a "neutral" rating and a $88.00 price target on the stock.
Low
Report
Blueprint Medicines Co. (NASDAQ: BPMC) is now covered by analysts at UBS Group AG. They set a "neutral" rating and a $88.00 price target on the stock.